Early access
Sign in
Not yet taking people in PortugalPhase 1

Compares how the body handles LY03010 and XEPLION in people with schizophrenia

Tests how the body processes LY03010 compared with XEPLION in adults with schizophrenia.

Key facts

Who runs it
Geneora Pharma (Shijiazhuang) Co. Ltd.
Where
Braga, Leiria, Touguinho, and Vila Nova de Gaia, PortugalSee the 4 sitesAlso in 3 other countries, 15 sites
Registry title
A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia
Status
Not yet recruiting
Phase
Phase 1
People taking part
170 people, planned
Started
1 Sept 2024
Planned end
31 Dec 2025
Type of study
Interventional
Record updated
27 August 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with schizophrenia. It compares LY03010 with XEPLION® in how the body absorbs and handles the drug.

Age
18 years or older
Sex
Women and men can join.

Where in Portugal

Also in 3 other countries, 15 sites

  • CCAB Centro Clinico Academico Braga AssociacaoBraga, PortugalNot yet recruiting
  • Centro Hospitalar De Leiria E.P.E.Leiria, PortugalNot yet recruiting
  • Hospitais Senhor Do Bonfim S.A.Touguinho, PortugalNot yet recruiting
  • Centro Hospitalar de Vila Nova de Gaia Espinho E P EVila Nova de Gaia, PortugalNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Compares how the body handles LY03010 and XEPLION in people with schizophreniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
27 August 2024